MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Charts
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
GERN stock logo

GERN

Geron Corporation

$1.54
0.01
 (0.65%)
Exchange:  NASDAQ
Market Cap:  987.942M
Shares Outstanding:  5.151M
Delayed data
Calculate GERN Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Harout Semerjian
Full Time Employees:  258
Address: 
919 East Hillsdale Boulevard
Foster City
CA
94404
US
Website:  https://www.geron.com
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron’s corporate headquarters are located in Foster City, California.

Click to read more…

Revenue Segmentation

MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/05/06 — Q1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue23776,994183,881
Gross Profit23775,738179,136
EBITDA-174,782-154,847-51,921
Operating Income-193,944-173,732-53,835
Net Income-184,127-174,572-85,782

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets394,076594,463570,540
Total Liabilities146,127313,461346,950
Total Stockholders Equity247,949280,320223,590
Total Debt85,899121,7160
Cash and Cash Equivalents71,13879,01679,440

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-167,103-218,618-111,037
Capital Expenditure-830-680-49
Free Cash Flow-167,933-219,298-111,086
Net Income-184,127-174,572-85,782
Net Change in Cash13,9299,738-1,436

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)861,648.844Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)1,111,665.796Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)933,801.500Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)-952,111.063Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)-737,978.446Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)-799,775.204Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)394,304.492Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)546,870.317Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)438,330.915Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)67,030,217.555Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)86,479,777.317Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)72,643,186.530Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)0.660Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)0.820Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)0.590Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)2Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)1Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
76.994M  ?P/S
 (TTM)
: 
4.77
?Net Income
 (TTM)
: 
-174572000  ?P/E
 (TTM)
: 
-15.25
?Enterprise Value
 (TTM)
: 
1.035B  ?EV/FCF
 (TTM)
: 
-9.01
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
-30.31%  ?ROIC
 (TTM)
: 
-8.32%
?Net Debt
 (TTM)
: 
-161917000  ?Debt/Equity
 (TTM)
: 
0.56
?P/B
 (TTM)
: 
4.66  ?Current Ratio
 (TTM)
: 
6.92

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
N/AResearch AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

Strengths (preview)

  • Company profile data indicates established sector positioning in biotechnology with defined leadership (CEO) and operational scale (full-time employees), supporting potential for targeted innovation in product segments.
  • Key metrics show positive gross profit margin TTM alongside current and quick ratios TTM, reflecting adequate short-term liquidity relative to liabilities.
  • Performance metrics include multi-period returns (1w to 5y) benchmarked against industry and sector averages, highlighting periods of outperformance that could signal resilience.

Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.

Log in to continue

Log in with Full Access for the complete SWOT analysis.

Login — it's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about GERN valuation

Is Geron Corporation (GERN) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Geron Corporation (GERN) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is GERN a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether GERN trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is GERN’s P/E ratio?

You can see GERN’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for GERN?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is GERN a good long-term investment?

Whether GERN fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

GERN

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

0.65
MARKETSnap

Trading Metrics:

Open: 1.54   Previous Close: 1.53
Day Low: 1.5   Day High: 1.54
Year Low: 1.04   Year High: 2.01
Price Avg 50: 1.43   Price Avg 200: 1.43
Volume: 3.943M   Average Volume: 12.63M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free

GERN full analysis

14/05/2026

Hey everyone, welcome back to the channel. Today we're diving deep into Geron Corporation, ticker GERN, a name that's been making serious moves lately in the biotech space with its first commercial product hitting the market. If you've been watching the charts, you know GERN has delivered some eye-popping short-term gains, but the bigger story is whether this commercial-stage company can turn its recent revenue surge into sustainable profitability. Let's break it all down together. Geron is a Foster City-based…

Listen to full analysis (audio file)

Open in MarketSnap Listen

Log in to continue

Log in to see the full analysis preview and audio links.

Login — it's free

See in Nexus

Relevant news

Geron Corp: Management's Plan Taking Shape As Competition Heats Up In Myelofibrosis
18-08-2026 09:58
Geron Corp: Management's Plan Taking Shape As Competition Heats Up In Myelofibrosis
Geron (GERN) Reports Q2 Loss, Beats Revenue Estimates
05-08-2026 10:01
Geron (GERN) Reports Q2 Loss, Beats Revenue Estimates
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
14-07-2026 16:26
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation: Commercial Performance Could Dovetail With IMpactMF Run-Up
01-07-2026 10:11
Geron Corporation: Commercial Performance Could Dovetail With IMpactMF Run-Up
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20-04-2026 16:05
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron: Time To Reconsider This Oversold Biotech
01-06-2026 05:53
Geron: Time To Reconsider This Oversold Biotech

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Philosophy
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlist & Portfolio Watchlist & Portfolio
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read